🔎 Trials Near Me

Home › Hyperlipoproteinemia Type II

Pag-aaral pangklinika para sa Hyperlipoproteinemia Type II na nagre-recruit sa U.S.

10 pag-aaral para sa Hyperlipoproteinemia Type II ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.

Mga lungsod na may pinakamaraming pag-aaral

Ayos sa estado

Mga pag-aaral na kamakailan lamang in-update

Opisyal na teksto ng pag-aaral (English)

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

Nagre-recruit
Lahat ng edad · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06743659

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Nagre-recruitPhase 1
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06164730

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Nagre-recruitPhase 2
Edad 18 hanggang 69 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT04941599

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Nagre-recruitPhase 3
Edad 2 hanggang 11 · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT06597006

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Nagre-recruitPhase 1
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT06451770

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Nagre-recruitPhase 3
Edad 6 hanggang 11 · Lahat ng kasarian · Na-update May 15, 2026 · NCT06597019

Comparing Direct vs Indirect Methods for Cascade Screening

Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT05348564

The ORIGIN-FH Study

Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT07470723

Atlantic Lipid Lowering Treatment Optimization Program

Nagre-recruit
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Ago 3, 2025 · NCT06439654

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.